Total Results: 7351
Even as drug pricing issues continue to draw scrutiny, federal safety regulations and incentives offer drug companies a new avenue to get a sweet return on their development costs.
The Trump administration has pledged to create jobs and shrink health care spending — almost a contradiction in a country where health care is a roaring engine of the economy.
With high drug prices creating widespread controversy, top pharmaceutical companies and their trade group vastly increased their lobbying spending on Capitol Hill.
Doctors are beginning to pay attention to injuries, such as brain damage or kidney failure, that can afflict people who survive an overdose.
Nearly half of state hospitals received a grade of C or lower for patient safety on a report card aimed at prodding them to do more to prevent injuries and deaths.
The chargemaster, a list detailing the official rate charged by a hospital for individual procedures, services and goods, is often kept in relative secrecy and is not regulated.
Led by Pfizer and Amgen, about 10 health care firms contributed to President Donald Trump’s inauguration, which earned them entry into private events with the president and vice president.
Readers react to and comment on recent stories.
The advocacy group behind an expensive media blitz opposing Canadian drug imports has deep ties to the drug industry’s largest trade group.
The powerful chairman of the Senate Judiciary Committee wants the Centers for Medicare and Medicaid Services to explain $125 million in overcharges by insurers.